Culley Brian M, President and CEO of Lineage Cell Therapeutics, Inc. ($LCTX), made one open market purchase of common shares worth $24,375 in the last 365 days, with the most recent on March 12, 2026. This ranks 3,673rd among 4,983 insiders in our database, where the average purchase totals $1.46 million across 3.29 transactions. Culley Brian M reported no open market sales during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 12, 2026 | Lineage Cell Therapeutics, Inc. | $LCTX | Culley Brian M | President and CEO | P | Common Shares | 15000 | $1.63 | 255,516.0000 | 230,328,000 | 6.24% | 0.01% |
| March 5, 2026 | Lineage Cell Therapeutics, Inc. | $LCTX | Culley Brian M | President and CEO | A | Employee Stock Option (Right to Buy) | 3250000 | $0.00 | 3,250,000.0000 | 230,328,000 | 9999.99% | 1.41% |
| Feb. 11, 2026 | Lineage Cell Therapeutics, Inc. | $LCTX | Culley Brian M | President and CEO | M | Restricted Stock Units | 31250 | $0.00 | 0.0000 | 230,328,000 | 100.00% | 0.01% |
| Feb. 11, 2026 | Lineage Cell Therapeutics, Inc. | $LCTX | Culley Brian M | President and CEO | F | Common Shares | 12869 | $1.80 | 240,516.0000 | 230,328,000 | 5.08% | 0.01% |
| Feb. 11, 2026 | Lineage Cell Therapeutics, Inc. | $LCTX | Culley Brian M | President and CEO | M | Common Shares | 31250 | $0.00 | 253,385.0000 | 230,328,000 | 14.07% | 0.01% |
| Dec. 19, 2025 | Lineage Cell Therapeutics, Inc. | $LCTX | Culley Brian M | President and CEO | A | Common Shares | 8925 | $0.00 | 222,469.0000 | 230,328,000 | 4.18% | 0.00% |
| Dec. 19, 2025 | Lineage Cell Therapeutics, Inc. | $LCTX | Culley Brian M | President and CEO | F | Common Shares | 334 | $1.68 | 222,135.0000 | 230,328,000 | 0.15% | 0.00% |
| March 10, 2025 | Lineage Cell Therapeutics, Inc. | $LCTX | Culley Brian M | President and CEO | A | Employee Stock Option (Right to Buy) | 2300000 | $0.00 | 2,300,000.0000 | 220,416,326 | 9999.99% | 1.04% |
| Feb. 11, 2025 | Lineage Cell Therapeutics, Inc. | $LCTX | Culley Brian M | President and CEO | M | Common Shares | 31249 | $0.00 | 226,091.0000 | 220,416,326 | 16.04% | 0.01% |
| Feb. 11, 2025 | Lineage Cell Therapeutics, Inc. | $LCTX | Culley Brian M | President and CEO | F | Common Shares | 12547 | $0.65 | 213,544.0000 | 220,416,326 | 5.55% | 0.01% |
| Feb. 11, 2025 | Lineage Cell Therapeutics, Inc. | $LCTX | Culley Brian M | President and CEO | M | Restricted Stock Units | 31249 | $0.00 | 31,250.0000 | 220,416,326 | 50.00% | 0.01% |
| Nov. 21, 2024 | Lineage Cell Therapeutics, Inc. | $LCTX | Culley Brian M | President and CEO | P | Common Shares | 40000 | $0.60 | 194,842.0000 | 174,987,000 | 25.83% | 0.02% |
| May 24, 2024 | Lineage Cell Therapeutics, Inc. | $LCTX | Culley Brian M | President and CEO | P | Common Shares | 10000 | $1.05 | 154,842.0000 | 174,987,000 | 6.90% | 0.01% |
| March 7, 2024 | Lineage Cell Therapeutics, Inc. | $LCTX | Culley Brian M | President and CEO | A | Employee Stock Option (Right to Buy) | 1900000 | $0.00 | 1,900,000.0000 | 174,987,000 | 9999.99% | 1.09% |
| Feb. 11, 2024 | Lineage Cell Therapeutics, Inc. | $LCTX | Culley Brian M | President and CEO | F | Common Shares, no par value | 12806 | $1.08 | 144,842.0000 | 174,987,000 | 8.12% | 0.01% |
| Feb. 11, 2024 | Lineage Cell Therapeutics, Inc. | $LCTX | Culley Brian M | President and CEO | M | Common Shares, no par value | 31249 | $0.00 | 157,648.0000 | 174,987,000 | 24.72% | 0.02% |
| Feb. 11, 2024 | Lineage Cell Therapeutics, Inc. | $LCTX | Culley Brian M | President and CEO | M | Restricted Stock Units | 31249 | $0.00 | 62,499.0000 | 174,987,000 | 33.33% | 0.02% |